Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Retrophin Announces Proposed Public Offering of 5,100,000 Shares of Common Stock

Business Wire March 16, 2015

Retrophin Reports Fourth Quarter and Full Year 2014 Financial Results

Business Wire March 5, 2015

Tim Coughlin Joins Retrophin's Board of Directors

Business Wire March 4, 2015

Launch of Turing Pharmaceuticals Announced - New Drug Company to Focus on Treating Unmet Medical Needs Across Broad Therapeutic Areas

PR Newswire February 24, 2015

Retrophin to Report Fourth Quarter and Full Year 2014 Financial Results

Business Wire February 19, 2015

Retrophin to Present at the 2015 Leerink Global Healthcare Conference

Business Wire February 5, 2015

Retrophin Announces Voting Results of Special Meeting of Stockholders

Business Wire February 3, 2015

Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion Pharmaceuticals

Business Wire January 12, 2015

The Shuman Law Firm Investigates Retrophin, Inc.

Business Wire January 9, 2015

Ryan & Maniskas, LLP Announces Investigation of Retrophin, Inc.

PR Newswire January 9, 2015

Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan

Business Wire January 9, 2015

Retrophin Provides Corporate Update

Business Wire January 9, 2015

Updated: Harwood Feffer LLP Announces Investigation of Retrophin, Inc.

PR Newswire January 8, 2015

Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 6, 2015

Attention Retrophin, Inc. (RTRX) Shareholders: Retrophin Mislead Investors According to a Newly Filed Class Action

GlobeNewswire December 22, 2014

UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Retrophin, Inc. and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX

GlobeNewswire December 16, 2014

Retrophin Announces Addition to the NASDAQ Biotechnology Index

Business Wire December 16, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Retrophin, Inc. of Class Action Lawsuit and Upcoming Deadline -- RTRX

GlobeNewswire December 12, 2014

INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Law Offices of Howard G. Smith

Business Wire December 12, 2014

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Retrophin, Inc. and Lead Plaintiff Deadline of December 19, 2014

PR Newswire December 12, 2014